公司资料
ALXN 股价、新闻与催化剂
- 股票代码:
- ALXN
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United States
股价为何变动
Current closing-price context is not available for ALXN.
公司概览
业务概览
Alexion Pharmaceuticals was a rare-disease biotechnology company known for complement biology and ultra-rare disease therapies before being acquired by AstraZeneca. Its business centered on high-value specialty medicines for severe, uncommon conditions.
所在地与行业分类
Alexion was headquartered in the United States and listed on NASDAQ before its acquisition. It occupied a rare-disease biopharma position with global commercial reach.
商业模式特征
The company relied on specialty drug commercialization, rare-disease access, and the durability of high-value orphan therapies. Investors historically watched launch performance, label breadth, and the sustainability of its rare-disease franchise.
生物医药行业定位
Alexion was a premium rare-disease biotech name with a strong commercial identity. It stood out because of its orphan-drug focus and the way a narrow portfolio could still create a large market value.
未来催化剂
近期新闻
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。